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Abstract: Nanomedicine, known as the application of nanotechnology in medicine, has been 
applied to overcome the problems of poor bioavailability, in vitro and in vivo stability, and 
targeted delivery in the preparation of pharmaceutical products. Sirolimus, a water-insoluble 
immunosuppressant, has been formulated into an oral solid dosage form by using NanoCrystal
® 
technology to increase the water solubility and thereby the bioavailability. The efﬁ  cacy, 
safety, and pharmacokinetic properties are not signiﬁ  cantly different between liquid and 
solid formulations except that less ﬂ  uctuation of sirolimus blood concentration was observed 
in solid dosage form. The tablet formulation offers the advantages of better palatability and 
more convenience for long-term use. Sirolimus tablets are not only a successful example of 
nanomedicine, but also a more cost-effective treatment in renal transplantation than cyclosporine 
and tacrolimus.
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Introduction to nanomedicine and issues of 
transplant rejection
It has been more than 51 years since the ﬁ  rst successful human kidney transplantation at 
the Peter Ben Brigham Hospital in Boston (Merrill et al 1956). Graft rejection is one of 
the greatest challenges to transplantation. It is the outcome of the natural response of the 
immune system to a foreign substance, or antigen. This complex process is mainly T-
lymphocyte mediated, although it involves serial interactions between foreign antigens, 
T lymphocytes, macrophages, cytokines (also known as lymphokines or interleukins), 
adhesion molecules (ie, co-stimulatory molecules), and membrane proteins that enhance 
binding of T lymphocytes and B lymphocytes (Halloran and Miller 1996; Valente 
and Alexander 1998). The goal of immunosuppressive therapy is to prevent and treat 
organ rejection as well as prolong graft and patient survival. With the development of 
immunosuppressive agents (Table 1), kidney transplantation has become one of the 
most important renal replacement therapies nowadays (Morris 2004).
During the “azathioprine era” from the 1960s to the early 1980s, 1-year cadaveric 
graft survival rate was around 60% (Morris 2004; Sayegh and Carpenter 2004). With 
the introduction in 1978 of cyclosporine, a calcineurin inhibitor (CNI), the 1-year 
graft survival rate increased to more than 80% (Sayegh and Carpenter 2004). In the 
1990s, the availability of several other immunosuppressive agents with different 
mechanisms of action (tacrolimus, mycophenolate mofetil, and sirolimus) made 
combination immunosuppressive therapy a general modality in organ transplantation. 
However, due to the potency of these agents and inter- and intra-individual variability 
in pharmacokinetics, dose individualization is required to maintain adequate 
immunosuppression while minimizing adverse reactions.
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Poor water solubility and bioavailability contribute 
to the complexity of dosing cyclosporine and sirolimus. 
Pharmaceutical companies have been formulating insoluble 
drugs into commercially available products and minimizing 
the problem of large intra- and inter-individual variability in 
pharmacokinetic proﬁ  les. A limited number of methods such 
as generation of ionized drugs, co-solvents, surfactants, soft-
gel technology, micronization, and nanotechnology have been 
utilized in formulating water-insoluble drugs. In addition, 
other particular drug carriers, such as emulsion, liposome, 
and polymeric micelle, are considered as alternative methods 
to deliver water insoluble drugs (Yokoyama 2005). For 
example, cyclosporine has been emulsiﬁ  ed by bile salts 
to form micelles and further modiﬁ  ed into microemulsion 
from the olive oil-based solution to enhance bioavailability 
(Thomas et al 2005). The liposomal formulation of tacrolimus 
also has been demonstrated as an effective strategy to increase 
efﬁ  cacy and decrease toxicity (McAlister et al 1999; Alemdar 
et al 2004). The formulation of amphiphilic block co-polymer 
micelles has been used to prepare injectable formulations of 
the highly lipophilic sirolimus (Ashok et al 2004; Forrest et 
al 2006).
After the introduction of tacrolimus (a CNI with a 
potency 32–100 times that of cyclosporine), less variation 
in bioavailability and not requiring bile salts for oral 
absorption made tacrolimus a better choice than cyclosporine 
(Sandimmune
®, Novartis) in liver transplantation (Scott et 
al 2003). This forced a reformulation of cyclosporine to 
retain its market share. The new formulation of cyclosporine 
(Neoral
®, Novartis) is a microemulsion utilizing 9.5% 
w/v alcohol, corn oil-mono-di-triglyceride, polyoxyl 40 
hydrogenated castor oil, and polyethylene glycol as vehicle 
(PDR 2006). This is an application of microtechnology to 
drug delivery, a breakthrough in the 1990s.
In the 2000s, a more advanced technology called 
nanotechnology was applied to medicine, which led to the 
emergence of nanomedicine (Weber 1999). Nanomedicine 
is the application of nanotechnology to medicine (Freitas 
2005). More broadly, it is the process of applying molecular 
tools and molecular knowledge of the human body in 
diagnosis, treatment, and prophylaxis of disease, as well 
as preserving and improving human health (Freitas 2005). 
Many nanomedicine technologies have been developed and 
are close to fruition. Among them, nanostructured materials 
such as fullerenes have been used in pharmaceuticals (Freitas 
2005). Sirolimus (Rapamune
®; Wyeth-Ayerst, Philadelphia, 
PA, USA)
 tablet is another example of the successful 
application of nanotechnology in pharmaceuticals to 
overcome the problems of formulation, poor bioavailability, 
and erratic absorption.
Chemistry, nanocrystal technology 
used, and formulation of sirolimus
Sirolimus is a triene marcolide antibiotic isolated from 
Streptomyces hygroscopicus (Vezina et al 1975; Sehgal 
1998). It is challenging to formulate sirolimus into either an 
intravenous or oral dosage form due to its water insolubility 
and a logP (log of the octanol-water partition coefﬁ  cient, 
a measure of a drug’s lipophilicity) of greater than 5. The 
solubility of sirolimus is 2.6  μg/mL, which is far below 
the target solution concentration of 1  mg/mL (Simamora 
et al 2001). It is impossible to enhance the solubility of 
sirolimus by the generation of a salt form because of the 
lack of an ionizable group of sirolimus in the pH range of 
1–10 (Simamora et al 2001). The solubility of sirolimus in 
a single organic solvent, such as ethanol, γ-butyrolactone, 
dimethyl isosobide, and glycerol formal (a mixture of 5-
hydroxy-1,3-dioxane and 4-hydroxymethyl-1,3-dioxolane 
Table 1  Immunosuppressive agents commonly used in 
transplantation 
Drugs    Indication in 
   transplantation 
Protein drugs  
Monoclonal antibody  
 Basiliximab  (Simulect
®)   Induction 
 Daclilzumab  (Zenapax
®)   Induction 
   Muromonab-CD3   Induction, treatment
(Orthoclone OKT3
®)   of rejection 
Polyclonal antibody  
  Antithymocyte immunoglobulin   Induction, treatment
 rabbit  (Thymoglobulin
®) of  rejection
  Antithymocyte immunoglobulin   Induction, treatment 
  equine (ATGAM® , Lymphoglobulin
®)   of rejection
Corticosteroids  
  Methylprednisolone   Treatment of rejection 
  Prednisone, prednisolone   Maintenance therapy 
Immunophilin-binding drugs  
Calcineurin inhibitors (CNI)  
 Cyclosporine  (Neoral
®, Sandimmune
®)   Maintenance therapy 
 Tacrolimus  (Prograf
®) Maintenance  therapy 
Mammalian target of rapamycin 
inhibitors (m-TOR inhibitor)  
 Sirolimus  (Rapamune
®)   Maintenance therapy 
 Everolimus  (Certican
®)   Maintenance therapy 
Antiproliferative agents  
Antimetabolites  
 Azathioprine  (Imuran
®)   Maintenance therapy 
Purine synthesis inhibitors  
  Mycophenolate mofetil (CellCept
®)   Maintenance therapy 
  Mycophenolate sodium (Myfortic
®)   Maintenance therapy International Journal of Nanomedicine 2007:2(1) 27
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in a ratio of 60:40), increases thousands-fold to greater 
than 90  mg/mL. Although a thousand-fold decrease in the 
solubility of sirolimus was observed in single cosolvent–
water mixtures, the solubility could be increased to more than 
10 mg/mL when it was prepared in multiple cosolvent and 
hydrotrope mixtures, such as 10% ethanol, 40% propylene 
glycol, 5% benzyl alcohol, and 3%–5% benzoate buffer 
(Simamora et al 2001). In 1999, the ﬁ  rst commercially 
available product of sirolimus was thus an oral solution with 
a concentration of 1 mg/mL in Phosal 50 PG (a dispersion 
of 50% phosphatidylcholine in a propylene glycol/ethanol 
carrier) and polysorbate 80 (PDR 2003). The taste, and the 
requirement for refrigerator storage, protection from light, 
and disposal of the oral syringe after a single use make 
the oily solution an inconvenient dosage form (Vasquez 
2000). 
To deliver sirolimus orally in a solid dosage form, the 
major problem of the dissolution of sirolimus from the dosage 
form had to be overcome, as well as its permeability across 
the biological barrier, such as ﬁ  rst-pass effect via intestinal 
and hepatic metabolism and efﬂ  ux transporter P-glycoprotein 
(Figure 1). It took one more year to explore the oral tablet 
formulation of sirolimus using NanoCrystal
® technology 
acquired by Elan Corporation (Rosen and Abribat 2005). 
This product, launched in 2002, offers greater palatability and 
convenience of administration and storage (at 20–25°C).
Sirolimus is formulated as nanometer-sized drug crystals 
by NanoCrystal technology using high-shear media mills. 
According to the Noyes-Whitney equation of dissolution 
Figure 1  Factors inﬂ  uencing the bioavailability of oral tablet sirolimus. Generally, the bioavailability of oral tablet sirolimus is determined by the solubility and 
permeability of sirolimus. The nanocrystalline sirolimus improves sirolimus dissolution, saturation solubility, and stability in gastrointestinal (GI) lumen and thereby 
improves the aborption. However, sirolimus is the substrate for the metabolic enzyme (cytochrome P450 3A) and efﬂ  ux transporter (P-glycoprtoein) in intestinal 
and hepatic cells. Therefore, less than 20% of sirolimus can reach systemic circulation.
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(Noyes and Whitney 1897), the rate of dissolution is 
proportional to the effective surface area (A) and the 
difference (Cs-C)/h: 
Dissolution rate =        (Cs-C).
Where D is the diffusion coefﬁ  cient of the drug, h is the 
thickness of diffusion boundary layer, Cs is the saturation 
solubility of the drug, and C is the concentration of drug in 
the medium. Nanocrystalline sirolimus not only increases the 
effective surface area (A) , but also increases the saturation 
solubility (Cs) and decreases the thickness of the diffusion 
boundary layer (h) (Muller et al 2001; Merisko-Liversidge 
et al 2003; Muller and Keck 2004). The saturation solubility 
can be increased only when the particle size is reduced in 
a submicron range (Muller and Keck 2004). In addition, 
it possesses long-term physical stability without Ostwald 
ripening (the tendency for larger particles to grow in diameter 
over time, while the smaller particles dissolve in a highly 
dispersed systems) due to the uniform nanometer-sized 
particles (Muller and Keck 2004). High adhesiveness on 
biological surfaces and high endocytosis of nanocrystalline 
drugs were also reported (Kayser 2000; Muller and Keck 
2004). Therefore, nanocrystalline sirolimus may provide a 
range of improvements in bioavailability, dose proportionality, 
absorption variability, and absorption rate.
In the process of sirolimus nanocystallization, generally 
recognized as safe (GRAS) stabilizers were added to avoid 
the agglomeration/aggregation of the drug crystals due 
AD
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to surface energy of nanocrystalline particles (Figure 2) 
(Merisko-Liversidge et al 2003). A mixture of non-ionic and 
ionic stabilizers, such as cellulosics, poloxamer, polysorbates, 
lecithin, sodium glycocholate and polyvinylpyrrolidones, 
is required to create a steric barrier and an electrostatic 
repulsion among particles, respectively (Patravale et al 
2004). The inactive ingredients of sirolimus tablet include 
microcrystalline cellulose, polyethylene glycol 8000, 
polyethylene glycol 20000, poloxamer 188, sucrose, lactose, 
calcium sulfate, pharmaceutical glaze, talc, titanium dioxide, 
magnesium stearate, povidone, glyceryl monooleate, 
carnauba wax, and other ingredients (PDR 2003). Some 
of the disclosed and concealed inactive GRAS ingredients 
were the essential components in the process of sirolimus 
nanocrystallization.
Immunopharmacology and 
pharmcokinetics of sirolimus
Sirolimus, with a chemical structure related to tacrolimus, 
is one of the most potent immunosuppressive agents for 
prevention of rejection (Sehgal 1998; Vasquez 2000). 
When combined with cyclosporine- or tacrolimus-based 
regimen in kidney transplantation, sirolimus increases 
immunosuppressive activity through a sequential synergistic 
mechanism.
Like cyclosporine and tacrolimus, sirolimus binds 
to cytosolic receptors, an intracellular protein, known as 
immunophilins (Figure 3). Cyclosporine binds to cyclophilin 
of the immunophilin family, forming a complex that then 
engages calcinueurin (Clipstone and Crabtree 1992). Both 
sirolimus and tacrolimus engage another immunophilin 
called FK-binding protein-12 (FKBP-12). Tacrolimus-FKBP 
complex, like cyclosporine-cyclophilin complex, inhibits 
the catalytic activity of calcineurin-calcium-calmodulin 
complex. The inhibition of calcineurin activity decreases 
the production of IL-2 and other cytokines, thereby blocking 
their activation of T-lymphocytes in the G0 and G1 phases of 
cell cycle.
In contrast, sirolimus-FKBP complex binds to the 
mammalian target of rapamycin (mTOR), thereby inhibiting 
T-lymphocyte proliferation through inhibition of interleukin-
2-mediated (IL-2-mediated) signal transduction in mid to late 
G1 phase and preventing cell-cycle progression from the G1 
phase to the S phase (Vathsala et al 1990; Sehgal 1998). It 
also inhibits IL-2 dependent and independent B-lymphocyte 
proliferation and antibody production (Aagaard-Tillery and 
Jelinek 1994).
Sirolimus oral solution has an oral bioavailability of about 
15% and distributes widely in tissue (volume of distribution 
19 L/kg; Yatscoff 1996; Mahalati and Kahan 2001). The mean 
oral bioavailability of sirolimus tablets is not signiﬁ  cantly 
different from that of oral solution (Kelly et al 1999; 
Hariharan and Zimmerman 2000; Kelly et al 2000; PDR 
2003). The tablets are not bioequivalent to the oral solution. 
However, clinical equivalence has been demonstrated at 
the 2-mg dose level (VanBuren 2000; PDR 2003). At doses 
Figure 2  The nanocrystalline sirolimus system. Generally recognized as safe (GRAS) stabilizers were milled with sirolimus into nanocrystal particles by 
NanoCrystal
® technology.
GRAS stabilizers
Sirolimus in normally
sized drug powder
Sirolimus in nanometer-
sized crystalline particles
low energy milling process
Dissolution rate
Surface area
Saturation solubility
Thickness of diffusion
boundary layerInternational Journal of Nanomedicine 2007:2(1) 29
Sirolimus nanomedicine in renal transplantation
between 3 and 12 mg/m
2, there is a linear correlation between 
the whole-blood concentration and dosage of sirolimus 
solution within the same transplant individuals (PDR 2003). 
The mean time-to-peak concentration (tmax) is about 1 hour 
after a single dose in healthy volunteers and 2 hours after 
multiple oral doses in renal transplant recipients (PDR 
2003). A study by Kelly et al (1999) indicated that there 
were no differences between the liquid and tablet in trough 
concentrations (C0) and area under the concentration–time 
curve (AUC) during dosage form conversion in stable kidney 
transplant recipients. However, tablets had a lower whole-
blood peak concentration (Cmax) and dose corrected Cmax. 
The tmax of tablets was longer, but was signiﬁ  cant only at 4 
weeks post-conversion. The inter-individual variability and 
percentage ﬂ  uctuation of sirolimus serum concentration 
were less in tablets than in liquids (Kelly et al 2000). These 
results indicate that sirolimus tablets provide more consistent 
immunosuppressive exposure over the dosing interval in each 
individual than the liquid formulation.
Sirolimus is metabolized extensively by liver enzymes, 
with only 2.2% excreted unchanged in urine (PDR 2003). 
A study by Wu et al (2005) found that the dose-adjusted 
trough concentration of sirolimus in patients with persistent 
liver enzyme elevation was signiﬁ  cantly higher than in those 
with normal liver function. Like cyclosporine and tacrolimus, 
sirolimus is a substrate for both cytochrome P450 (CYP) 3A 
and P-glycoprotein (P-gp) (Sattler et al 1992; Turgeon et al 
1994; Lampen et al 1995; Fricker et al 1996; Yatscoff 1996; 
Lown et al 1997; Masuda et al 2000), and thus has potential 
drug interactions similar to those of CNIs. In addition, the 
potential drug interactions between CNIs and sirolimus 
have been a concern. Sirolimus did not signiﬁ  cantly affect 
the pharmacokinetics of either an olive oil-based or the 
microemulsion-formulated cyclosporine in human studies 
(Zimmerman and Kahan 1997; Kahan et al 1998; MacDonald 
et al 2000). A limited number of available studies did not 
reveal an effect of tacrolimus on the pharmacokinetics of 
sirolimus (MacDonald et al 2000; McAlister et al 2002; 
Kuypers et al 2003; Undre 2003). However, both an olive 
oil-based or the microemulsion-formulated cyclosporine 
may increase the bioavailability of sirolimus (PDR 2003). 
In addition, the bioavailability and trough concentrations 
of sirolimus are signiﬁ  cantly higher when microemulsion-
formulated cyclosporine and sirolimus are administered 
concomitantly than when they are staggered by 4 hours 
(Kaplan et al 1998; MacDonald et al 2000; PDR 2003). Thus, 
the manufacturer of sirolimus, Wyeth Ayerst (Philadelphia, 
PA), has suggested that the two drugs be given 4 hours apart. 
However, a randomized, parallel-group study has shown that 
during multiple-dose administration, the bioavailability and 
trough concentration of sirolimus were, respectively, 1.46 
and 1.42 times higher in the cyclosporine group than in the 
tacrolimus group, even though sirolimus was administered 6 
hours after CNIs (Wu et al 2005). Staggered administration 
cannot completely prevent a drug interaction between 
cyclosporine and sirolimus solution. Whether sirolimus 
tablets exert the same drug interaction with cyclosporine 
remains to be studied.
Efﬁ  cacy, comparative studies, and 
prolonged therapy
In September 1999, sirolimus was approved by the US Food 
and Drug Administration (FDA) for use in combination with 
cyclosporine and steroids. In November 2000, the drug was 
registered by the European Agency as an alternative to CNI 
for maintenance therapy. In April 2003, the FDA approved a 
new regimen to reduce the use of cyclosporine by substituting 
higher doses of sirolimus (Kahan 2004).
The safety and efﬁ  cacy of sirolimus oral solution and 
tablets for the prevention of graft rejection following 
kidney transplantation has been compared in a 477-patient, 
randomized, multicenter, controlled trial. There was no 
signiﬁ  cant difference between the oral solution and tablet 
formulation for rejection, graft, and patient survival at 3, 6, 
and 12 months after transplantation (VanBuren 2000; PDR 
2003).
A CNI-free sirolimus-based protocol may avoid CNI 
Figure 3  Mechanism of action of cyclosporine, tacrolimus, and sirolimus. 
Adapted with permission from Wu FL, Tsai MK, et al. 2005. Effects of 
conversion from sirolimus oral solution to tablets in stable Taiwanese renal 
transplant recipients. J Formos Med Assoc, 104:22-8. © The Formosan Medical 
Association.
Abbreviations: CsA, cyclosporine; Ca, calcium; FK506, tacrolimus; KBP, 
FK binding protein; INF-γ, γ-interferon; IL, interleukin; mTOR; mammalian 
target of rapamycin; RAD; everolimus; SRL, sirolimus.
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nephrotoxicity. The incidences of acute rejection, chronic 
graft failure, and graft loss associated with this sirolimus-
based therapy were 19%, 14%, and 10%, respectively (Kahan 
2004). The long-term beneﬁ  ts with sirolimus-based therapy 
after early cyclosporine withdrawal have been demonstrated 
by Kreis et al (2004). Lipid proﬁ  les were similar between 
groups, while blood pressures and incidence of abnormal 
kidney function, edema, hyperuricemia, hyperkalemia, 
gingival hyperplasia, and Herpes zoster were signiﬁ  cantly 
lower in the sirolimus-based therapy. Recipients with low to 
moderate rejection risk may consider stopping cyclosporine 
2–4 months after transplantation (Halloran 2004; Kreis et 
al 2004). Compared with other immunosuppressive agents, 
regimens containing sirolimus have a lower incidence of 
cytomegalovirus (CMV) and BK polyoma virus infection 
(Halloran 2004; Kahan 2004).
Different from other immunosuppressive agents, 
m-TOR inhibitors may have antineoplastic and arterial 
protective effects. Sirolimus slows the growth of established 
experimental tumors (Guba et al 2002). According to Kahan’s 
study group (Kahan 2004), sirolimus therapy oughtweighs 
other immunosuppressive agents in the low incidence of 
malignancy. Compared with the general US population, 
the sirolimus/cyclosporine therapy showed equal incidence 
of skin cancers, and a 4-fold increase in post-transplant 
lymphoproliferative disorder (PTLD) and renal cell 
carcinoma. It was also reported to inhibit the progression 
of dermal Kaposi’s sarcoma in kidney-transplant recipients 
while providing effective immunosuppression (Stallone et al 
2005). The incidence of Kaposi’s sarcoma among solid organ 
recipients is about 500 times that in the general population 
(Hayward 2003). Three months after switching from 
cyclosporine to sirolimus in 15 kidney-transplant recipients 
who had biopsy-proven Kaposi’s sarcoma, all cutaneous 
Kaposi’s sarcoma lesions disappeared in all patients (Guba 
et al 2002).
Incorporation of sirolimus into coronary stents inhibits 
restenosis (Morice et al 2002; Dibra et al 2005). Combination 
of everolimus with CNIs reduced the incidence of graft 
coronary artery disease associated with heart transplantation 
(Eisen et al 2003). However, the potential arterial protective 
effects of m-TOR inhibitors must be weighed against their 
hyperlipidemia side-effect (Blum 2002).
Tolerability
The major adverse reactions of sirolimus include hyper-
lipedemia, thrombocytopenia, and impaired wound 
healing (PDR 2003). Delayed recovery from acute tubular 
necrosis in kidney transplants, aggravation of proteinuria, 
mouth ulcers, pneumonitis, and skin lesions were also 
reported (Halloran 2004). Theoretically, sirolimus should 
not cause nephrotoxicity due to lack of CNI activity 
(Sehgal 1998). Its combination with CNIs was expected to 
decrease nephrotoxicity of CNIs due to dose reduction of 
CNIs (McAlister et al 2000; Kahan and Camardo 2001). 
However, the combinations have been reported to increase 
nephrotoxicity, the hemolytic-uremic syndrome, and 
hypertension (Gonwa et al 2003; Halloran 2004). It should 
be noted that the dose and whole-blood concentrations of 
CNIs and sirolimus should be taken into consideration in 
interpreting these data. For example, in the study by Gonwa et 
al (2003), there was no difference between the two groups in 
median tacrolimus whole-blood trough concentration (8.5 ng/
mL and 8.7  ng/mL in the sirolimus- and mycophenolate-
treatment groups, respectively). That is, there was no dose 
reduction of tacrolimus in the sirolimus-treatment group. The 
median sirolimus dose was 3 mg/day with a corresponding 
median whole-blood trough concentration 7.3  ng/mL at 
6 months, which was higher than 2  mg/day (the dosage 
usually recommended). Dose reduction of CNIs as well 
as minimizing the dose of sirolimus is crucial to minimize 
toxicity of this combination. Withdrawing one of the drugs in 
the combination of a m-TOR inhibitor and cyclosporine can 
also reduce renal dysfunction and hypertension, with a small 
increase in rejection episodes (Johnson et al 2001).
Pharmacoeconomic data and 
patient acceptability
With the help of the nanotechnology, tablet formulation of 
sirolimus was successfully introduced onto the market one 
year after the launch of the oil-based liquid formulation. 
Patient satisfaction is greater with sirolimus tablet than oil-
based liquid form because of improvement in palatability, 
less restricted storage conditions, and greater convenience 
of administration. Tablet sirolimus is now the preferred 
dosage form except in those who require a lower dose or 
cannot take tablets.
Sirolimus has been recognized as a potent immuno-
suppressive agent with less nephrotoxicity than CNIs, such 
as tacrolimus and cyclosporine. The cost-effectiveness 
and cost-utility studies of sirolimus versus tacrolimus and 
cyclosporine in kidney transplant patients have been reported 
by McEwan et al (2005, 2006). A stochastic simulation 
model was developed using clinical trial and observational 
data to forecast the incidence of graft failures, hemodialysis, 
peritoneal dialysis, retransplants, and acute rejections. Using International Journal of Nanomedicine 2007:2(1) 31
Sirolimus nanomedicine in renal transplantation
historical data on 937 renal transplant recipients, the costs of 
the different events from the perspective of the UK National 
Health Service, valued at 2003 prices with discount, were 
then used to evaluate both cost-effectiveness and cost-
utility over 10 and 20 years after transplantation (McEwan 
et al 2005, 2006). Treatment with sirolimus was projected 
to gain 0.72 and 1.8 discounted years of functioning graft 
over tacrolimus over 10-year and 20-year time horizons, 
respectively (McEwan et al 2005). Similarly, when compared 
with cyclosporine, sirolimus gained 0.6 and 1.59 discounted 
years of functioning graft and a cost saving of US$486 
and US$13033 per patient over 10-year and 20-year time 
horizons, respectively (McEwan et al 2006).
Conclusions
Sirolimus is one of the most potent immunosuppressive 
agents in transplantation which is useful in combination 
with CNI or as an alternative to CNI for maintenance 
therapy. Although sirolimus is correlated with higher 
incidence of hyperlipedemia, thrombocytopenia, impaired 
wound healing, delayed graft function, proteinuria, mouth 
ulcers, pneumonitis, and skin lesions, it has antineoplastic 
and arterial protective effects, and is associated with lower 
incidence of CMV infection in transplant recipients. With 
the application of nanotechnology, NanoCrystal formulation 
overcomes the problems of formulation, poor bioavailability, 
and erratic absorption of sirolimus. The tablet formulation 
has a better palatability, and is more convenient for long-term 
use. In addition, cost-effectiveness and cost-utility analysis 
also demonstrated the beneﬁ  ts of long-term use of sirolimus 
in kidney transplantation. Using nanocrytalline sirolimus 
as a successful prototype, nanotechnology is a prominent 
approach in the formulation of water-insoluble drugs for 
clinically applicable dosage forms in the future.
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